<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

Granta-519

Description

GRANTA-519 (Mantle Cell Lymphoma CDX Model) 

The GRANTA-519 cell line was derived from a patient with mantle cell lymphoma (MCL). It represents an aggressive non-Hodgkin’s lymphoma subtype with poor outcomes. GRANTA-519 is a well-established model for hematology drug research. Its biology reflects clinically relevant features of MCL progression. 

Key Features: 

  • Derived from mantle cell lymphoma. 
  • B-cell non-Hodgkin’s lymphoma model. 
  • Aggressive growth in xenograft settings. 
  • Suitable for hematology research. 

Applications: 
GRANTA-519 is applied in studies of MCL drug discovery and biomarker development. It supports evaluation of novel agents targeting B-cell malignancies. Researchers use it to study signaling pathways and therapy resistance. Its reproducibility makes it valuable for translational lymphoma research.

Details
Tumor Type
Lymphoma
Tumor Subtype
B cell lymphoma
Organism
Human
Mouse Sex
Female
Mouse Strain
NOG
Mutated Genes
ATM
Mutation: p.R2832C
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic & Pathogenic / Likely Pathogenic
Effect: Splice Acceptor Variant
Impact: Not Provided
TYRO3
Mutation: p.K235AfsTer18
Effect: Frameshift Variant, Splice Region Variant
Lumin Data
Proteomics RNASeq WES
Expression Data
Growth Curve
View on Lumin